Last reviewed · How we verify
Octagam (IVIG)
Octagam is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens.
Octagam is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome).
At a glance
| Generic name | Octagam (IVIG) |
|---|---|
| Also known as | Intravenous immunoglobulin 0.4 g/kg given as infusion |
| Sponsor | Oslo University Hospital |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Target | Multiple (polyvalent IgG; Fc receptors, complement system) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IVIG contains polyvalent immunoglobulins (primarily IgG) extracted from pooled human plasma. It works through multiple mechanisms including opsonization of pathogens, complement activation, neutralization of toxins and autoantibodies, and modulation of inflammatory cytokine production. It is used to treat immunodeficiency states and autoimmune/inflammatory conditions.
Approved indications
- Primary immunodeficiency disorders
- Secondary immunodeficiency
- Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome)
Common side effects
- Headache
- Fever
- Chills
- Myalgia
- Infusion reactions
- Thrombosis (rare)
- Aseptic meningitis (rare)
Key clinical trials
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm
- Determinants of Digestive Morbidity in Neonatal Jaundice
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (PHASE3)
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octagam (IVIG) CI brief — competitive landscape report
- Octagam (IVIG) updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI